Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Pharvaris N.V. PHVS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • NL • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$45.60
+59%

Pharvaris N.V. (PHVS) is a Biotechnology company in the Healthcare sector, currently trading at $28.68. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is PHVS = $46 (+59% upside).

Valuation: PHVS trades at a trailing Price-to-Earnings (P/E) of -7.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.59.

Net income is $134M (loss), growing at -47.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $776,798 against $271M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 10.11 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $301M.

Analyst outlook: 10 / 11 analysts rate PHVS as buy (91%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$45.60
▲ 59% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Pharvaris N.V., the average price target is $45.60, with a high forecast of $60.00, and a low forecast of $38.00.
Highest Price Target
$60.00
Average Price Target
$45.60
Lowest Price Target
$38.00

PHVS SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 88/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PHVS

✓
VALUE Pass
88/100
PHVS trades at a trailing Price-to-Earnings (P/E) of -7.9 (S&P 500 average ~25). Forward PEG 0.59 — Peter Lynch undervalued (≤1.0). Trailing PEG 1.54. Analyst consensus target is $46, implying +60.4% from the current price $29. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
PHVS: +0%/yr revenue is, -47.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet PHVS: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 10.11 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
PHVS: Gross margin is 0% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 10 / 11 analysts rate PHVS as buy (91%). Analyst consensus target is $46 (+60.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range11.51-29.85
Volume134.42K
Avg Volume (30D)163.45K
Market Cap$1.88B
Beta (1Y)-2.58
Share Statistics
EPS (TTM)-2.48
Shares Outstanding$54.02M
IPO Date2021-02-05
Employees108
CEOBerndt Axel Edvard Modig
Financial Highlights & Ratios
EBITDA$-145.59M
Net Income$-134.22M
Operating Income$-145.69M
Total Cash$291.68M
Total Debt$776.8K
Net Debt$-290.9M
Total Assets$301.45M
Price / Earnings (P/E)-11.6
Analyst Forecast
1Y Price Target$41.00
Target High$60.00
Target Low$38.00
Upside+43.0%
Rating ConsensusBuy
Analysts Covering11
Buy 91% Hold 9% Sell 0%
Price Target Summary
Company Info
CountryNL
ExchangeNASDAQ Global Select
CurrencyUSD
ISINNL00150005Y4

Price Chart

Track all markets on TradingView
PHVS
Pharvaris N.V. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
11.51 52WK RANGE 29.85

People Also View

STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 TYRA
TYRA
Tyra Biosciences, Inc.
$35.27
-0.98%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 JANX
JANX
Janux Therapeutics, Inc.
$15.24
+2.28%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message